Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression

BACKGROUND: The success of HER2-positive (HER2+) breast cancer treatment with trastuzumab, an antibody that targets HER2, relies on immune response. We demonstrated that TNFα induces mucin 4 (MUC4) expression, which shields the trastuzumab epitope on the HER2 molecule decreasing its therapeutic effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruni, Sofia, Mauro, Florencia L, Proietti, Cecilia J, Cordo-Russo, Rosalia I, Rivas, Martin A, Inurrigarro, Gloria, Dupont, Agustina, Rocha, Dario, Fernández, Elmer A, Deza, Ernesto Gil, Lopez Della Vecchia, Daniel, Barchuk, Sabrina, Figurelli, Silvina, Lasso, David, Friedrich, Adrián D, Santilli, María C, Regge, María V, Lebersztein, Gabriel, Levit, Claudio, Anfuso, Fabiana, Castiglione, Teresa, Elizalde, Patricia V, Mercogliano, Maria F, Schillaci, Roxana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016294/
https://www.ncbi.nlm.nih.gov/pubmed/36889811
http://dx.doi.org/10.1136/jitc-2022-005325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016294/
https://www.ncbi.nlm.nih.gov/pubmed/36889811
http://dx.doi.org/10.1136/jitc-2022-005325

Ejemplares similares